Clinical Trial Update: Effectiveness, Safety and Feasibility of HECT-CL, in Quetta, Pakistan [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating HECT-CL for cutaneous leishmaniasis in Quetta, Pakistan has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Leishmaniasis

Drugs mentioned

• HECT-CL (HECT-CL)

Snippet

Sponsor: Medecins Sans Frontieres, Netherlands | Conditions: Cutaneous Leishmaniases | Phase 3 | Status: TERMINATED